• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
NextCure, Inc. (NXTC) Stock Price, News & Analysis

NextCure, Inc. (NXTC) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.19

-$0.1

(-7.75%)

Day's range
$1.16
Day's range
$1.3
50-day range
$1.16
Day's range
$1.6
  • Country: US
  • ISIN: US65343E1082
52 wk range
$1.03
Day's range
$2.57
  • CEO: Mr. Michael S. Richman MSBA
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -5.57
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (NXTC)
  • Company NextCure, Inc.
  • Price $1.19
  • Changes Percentage (-7.75%)
  • Change -$0.1
  • Day Low $1.16
  • Day High $1.30
  • Year High $2.57

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $3.00
  • High Stock Price Target $3.00
  • Low Stock Price Target $3.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.28
  • Trailing P/E Ratio -0.61
  • Forward P/E Ratio -0.61
  • P/E Growth -0.61
  • Net Income $-62,723,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

NextCure, Inc. Frequently Asked Questions

  • What is the NextCure, Inc. stock price today?

    Today's price of NextCure, Inc. is $1.19 — it has decreased by -7.75% in the past 24 hours. Watch NextCure, Inc. stock price performance more closely on the chart.

  • Does NextCure, Inc. release reports?

    Yes, you can track NextCure, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the NextCure, Inc. stock forecast?

    Watch the NextCure, Inc. chart and read a more detailed NextCure, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is NextCure, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by NextCure, Inc. stock ticker.

  • How to buy NextCure, Inc. stocks?

    Like other stocks, NXTC shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is NextCure, Inc.'s EBITDA?

    NextCure, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in NextCure, Inc.’s financial statements.

  • What is the NextCure, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in NextCure, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including NextCure, Inc.'s financials relevant news, and technical analysis. NextCure, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for NextCure, Inc. stock currently indicates a “sell” signal. For more insights, review NextCure, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.